MX2022013210A - Uso de polipeptidos analogos de amilina humana para proporcionar control glucemico superior a diabeticos tipo 1. - Google Patents
Uso de polipeptidos analogos de amilina humana para proporcionar control glucemico superior a diabeticos tipo 1.Info
- Publication number
- MX2022013210A MX2022013210A MX2022013210A MX2022013210A MX2022013210A MX 2022013210 A MX2022013210 A MX 2022013210A MX 2022013210 A MX2022013210 A MX 2022013210A MX 2022013210 A MX2022013210 A MX 2022013210A MX 2022013210 A MX2022013210 A MX 2022013210A
- Authority
- MX
- Mexico
- Prior art keywords
- type
- amylin analog
- diabetics
- glycemic control
- human amylin
- Prior art date
Links
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 title abstract 2
- 230000002641 glycemic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con la administración de análogos de amilina humana para el tratamiento de diabetes tipo 1. Los métodos descritos en el presente documento mejoran la terapia de inyección o infusión de insulina con la administración conjunta continua y separada de un análogo de amilina a una dosis terapéuticamente efectiva de al menos 5 mg por kilogramo por día o a una dosis terapéuticamente efectiva que es equivalente a al menos la dosis ED70 del análogo de amilina, tal como se define en el presente documento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063012619P | 2020-04-20 | 2020-04-20 | |
| PCT/US2021/028209 WO2021216586A1 (en) | 2020-04-20 | 2021-04-20 | Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013210A true MX2022013210A (es) | 2023-05-19 |
Family
ID=78270144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013210A MX2022013210A (es) | 2020-04-20 | 2021-04-20 | Uso de polipeptidos analogos de amilina humana para proporcionar control glucemico superior a diabeticos tipo 1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230158116A1 (es) |
| EP (1) | EP4138780A4 (es) |
| JP (1) | JP2023522944A (es) |
| KR (1) | KR20230040943A (es) |
| CN (1) | CN116018156A (es) |
| AU (1) | AU2021260870A1 (es) |
| CA (1) | CA3175810A1 (es) |
| IL (1) | IL297389A (es) |
| MX (1) | MX2022013210A (es) |
| WO (1) | WO2021216586A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814600A (en) * | 1991-05-24 | 1998-09-29 | Amylin Pharmaceuticals Inc. | Method and composition for treatment of insulin requiring mammals |
| US7910548B2 (en) * | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
| NZ561361A (en) * | 2005-02-11 | 2010-02-26 | Amylin Pharmaceuticals Inc | GIP hybrid polypeptides with at least two hormonal activities |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| WO2015196174A1 (en) * | 2014-06-20 | 2015-12-23 | Greene Howard E | Infusion delivery devices and methods |
| AU2016232218B2 (en) * | 2015-03-18 | 2020-09-10 | Boehringer Ingelheim International Gmbh | Amylin analogues |
| AU2019357621A1 (en) * | 2018-10-11 | 2021-05-27 | Intarcia Therapeutics, Inc. | Human amylin analog polypeptides and methods of use |
-
2021
- 2021-04-20 JP JP2022564043A patent/JP2023522944A/ja active Pending
- 2021-04-20 US US17/996,131 patent/US20230158116A1/en active Pending
- 2021-04-20 IL IL297389A patent/IL297389A/en unknown
- 2021-04-20 WO PCT/US2021/028209 patent/WO2021216586A1/en unknown
- 2021-04-20 CN CN202180029936.5A patent/CN116018156A/zh active Pending
- 2021-04-20 EP EP21793746.5A patent/EP4138780A4/en active Pending
- 2021-04-20 KR KR1020227036826A patent/KR20230040943A/ko active Search and Examination
- 2021-04-20 CA CA3175810A patent/CA3175810A1/en active Pending
- 2021-04-20 AU AU2021260870A patent/AU2021260870A1/en active Pending
- 2021-04-20 MX MX2022013210A patent/MX2022013210A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230158116A1 (en) | 2023-05-25 |
| EP4138780A4 (en) | 2024-05-15 |
| AU2021260870A1 (en) | 2022-12-08 |
| EP4138780A1 (en) | 2023-03-01 |
| KR20230040943A (ko) | 2023-03-23 |
| CA3175810A1 (en) | 2021-10-28 |
| JP2023522944A (ja) | 2023-06-01 |
| CN116018156A (zh) | 2023-04-25 |
| WO2021216586A1 (en) | 2021-10-28 |
| IL297389A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodbard et al. | Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials | |
| AU762481C (en) | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders | |
| JP2013522194A5 (es) | ||
| HK1177901A1 (en) | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin 10--10- t | |
| HK1079703A1 (zh) | 通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法 | |
| Giugliano et al. | Comment on American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016; 39 (Suppl. 1): S52–S59 | |
| CR20220641A (es) | Compuestos de insulina acilada de acción temporal prolongada | |
| Woo | A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus | |
| MX2023000398A (es) | Analogos de insulina novedosos y usos de estos. | |
| MX2022013210A (es) | Uso de polipeptidos analogos de amilina humana para proporcionar control glucemico superior a diabeticos tipo 1. | |
| MX2021002090A (es) | Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto. | |
| Boudjenah | Advocacy for Carbomedtherapy (Carbon Dioxide Therapy) in the Treatment of Diabetic Neuropathy | |
| MX2022008748A (es) | Administración oral de péptidos. | |
| EA200600757A1 (ru) | Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете | |
| Woo et al. | 92-Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter-2 Inhibitor: A Posthoc Analysis of SUSTAIN 9 | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| SULLIVAN | Metformin Cut Deaths in Patients at Risk for CVD | |
| Casutt et al. | Projected complex sensations after interscalene brachial plexus block | |
| RU2348417C1 (ru) | Способ коррекции нейроэндокринного и иммунного состояния организма (варианты) | |
| Barag et al. | The role of emerging insulin and regimens in overcoming insulin treatment resistance | |
| CA3150837A1 (en) | Avocatin b for the treatment of diseases and conditions | |
| Rai et al. | Use of parathyroid hormone analog (Teriparatide) in patients with chronic hypoparathyroidism after total thyroidectomy: a case report | |
| BRUNTON | Safety and effectiveness of modern insulin therapy | |
| Unger | An Evidence-Based Insulin Intensification Regimen | |
| Woldenberg | Clinical evaluation of colloidal sulphur in the treatment of arthritis |